Top Page
Zelira Therapeutics
(OTC:ZLD)
Zelira Therapeutics (ZLD) vs. iShares MSCI Australia ETF (EWA)
Zelira Therapeutics Business Overview & Revenue Model
Zelira Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 655.00 | 656.00 | 94.95K | 301.12K | 1.54M | 663.32K |
| Gross Profit | -802.95K | -802.95K | 10.28K | -3.22M | -5.72M | -39.16K |
| EBITDA | -4.17M | -4.17M | -36.44M | -6.79M | -13.06M | -9.41M |
| Net Income | -3.63M | -3.63M | -36.57M | -5.57M | -11.95M | -8.55M |
Balance Sheet | ||||||
| Total Assets | 1.30M | 1.30M | 5.18M | 33.89M | 37.70M | 39.37M |
| Cash, Cash Equivalents and Short-Term Investments | 5.66K | 5.66K | 586.16K | 146.21K | 2.75M | 4.97M |
| Total Debt | 2.14M | 2.14M | 5.95M | 437.90K | 500.91K | 551.08K |
| Total Liabilities | 5.59M | 5.59M | 9.36M | 2.18M | 2.01M | 1.54M |
| Stockholders Equity | -4.46M | -4.46M | -4.51M | 31.80M | 35.20M | 37.83M |
Cash Flow | ||||||
| Free Cash Flow | -4.91M | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Operating Cash Flow | -4.91M | -4.91M | -4.39M | -7.25M | -9.43M | -8.62M |
| Investing Cash Flow | 1.15M | 1.15M | 919.74K | 2.83M | -207.78K | 1.38M |
| Financing Cash Flow | 3.19M | 3.19M | 3.92M | 1.77M | 7.10M | 10.53M |
Zelira Therapeutics Technical Analysis
Zelira Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$8.64M | -19.84 | -8.72% | ― | ― | 71.10% | |
54 Neutral | AU$33.26M | -8.33 | -16.65% | ― | ― | -672.73% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$36.73M | -9.09 | -143.71% | ― | 306.88% | ― | |
41 Neutral | AU$4.64M | -1.31 | ― | ― | -99.31% | 90.20% | |
37 Underperform | AU$6.89M | -1.61 | -628.72% | ― | ― | 31.87% |
Zelira Therapeutics Corporate Events
Zelira Therapeutics announced a change in the interest of its director, Oludare Odumosu, involving the acquisition of 386,847 convertible notes. This change reflects the issuance of convertible notes to replace a Convertible Loan Agreement, which was approved by shareholders, potentially impacting the company’s financial structure and signaling strategic financial adjustments.
Zelira Therapeutics Limited announced the issuance of 580,270 unquoted convertible notes as part of a previously announced transaction. This move is part of the company’s strategic financial management, potentially impacting its capital structure and providing additional resources for its ongoing projects and market expansion efforts.
Zelira Therapeutics has received a $1,070,000 cash refund from the Australian Federal Government’s R&D Tax Incentive Scheme. This refund will support the company’s ongoing clinical and product development programs, as well as initiatives for pipeline products and essential business operations, thereby strengthening its position in the cannabis medicine industry.
Zelira Therapeutics Limited has announced a proposed issue of securities, specifically a convertible note, with a maximum of 580,271 securities to be issued. This move is part of their strategy to raise capital, potentially impacting the company’s financial position and market operations as they continue to expand their offerings in the cannabinoid-based medicine sector.
Zelira Therapeutics’ 2025 Annual General Meeting highlighted the company’s focus on validating its operational scale. The announcement underscores Zelira’s strategic intentions and future plans, acknowledging the inherent risks and uncertainties in achieving these objectives. The company’s efforts to expand its operational capabilities are crucial for its positioning in the cannabinoid therapeutics industry, with potential implications for stakeholders as it navigates market challenges.
Zelira Therapeutics has announced a non-dilutive R&D loan facility secured against its anticipated R&D tax incentive rebate for FY25, which will be used to advance the HOPE® SPV clinical trial and general working capital. Additionally, the company’s directors have provided unsecured loan notes to support operations. The company is making significant progress in its FDA program for the HOPE® clinical trial, with plans to launch Phase 1 trials for its HOPE® 1 Phelan McDermid Syndrome program. This development is part of Zelira’s strategy to bring effective cannabinoid-based therapies to market, targeting ultra-rare genetic conditions and improving patient outcomes.
Zelira Therapeutics Limited announced the cessation of 125,723 securities due to the expiry of options or other convertible securities without exercise or conversion. This development may impact the company’s capital structure and could influence investor perceptions and market positioning as the company continues its strategic initiatives.
Zelira Therapeutics has announced its upcoming Annual General Meeting, scheduled for November 19, 2025, which will be held both virtually and physically in Perth. Key agenda items include the adoption of the remuneration report, re-election of director Greg Blake, and approval of convertible notes for Dr. Oludare Odumosu and Dr. Donna Gentile O’Donnell. Additionally, the company seeks to renew its proportional takeover provisions in the constitution. These resolutions, if passed, could impact the company’s governance and financial strategies, potentially influencing shareholder value and market perception.
Zelira Therapeutics has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement outlines the company’s adherence to ASX Corporate Governance Council’s principles, detailing the roles and responsibilities of the board and management, and the processes for director appointments and accountability, thereby reinforcing its commitment to transparency and effective governance practices.
Zelira Therapeutics announced that its Managing Director, Dr. Oludare Odumosu, and Non-Executive Director, Dr. Donna Gentile O’Donnell, will provide a total of USD$150,000 in unsecured loan notes to the company. These funds will be used for general working capital purposes. The loan notes, subject to shareholder approval, may be converted into shares at a premium price, reflecting favorable terms for the company amidst current market conditions. This strategic financial move is expected to bolster Zelira’s operational capabilities and strengthen its market position.